Circulating tumour cells (CTCs) 
Introduction
To date, many studies have reported on the prognostic significance of circulating tumour cells (CTCs) detection in metastatic breast cancer (MBC) [1] . The [2] . In the remaining 40% of patients with metastasis disease, CTC are undetected [3] . Because of CTC genetic and phenotypic heterogeneity, it is theoretically possible that CTC that express EpCam will not express cytokeratins, thus resulting undetected by the CellSearch system. In breast cancer, specifically, loss of CK has been described as an indicator of aggressive disease, and found associated to reduced OS and unfavourable prognostic factors as HR negativity [4] . In this context, it has been suggested that epithelial-to-mesenchymal transition (EMT), which is characterized by loss of CK and gain of mesenchymal markers as vimentin and fibronectin, may be implicated in CTC formation in breast cancer [5] .
Recently, it has been observed [6] . This difference was found statistically significant (P ϭ 0.000) (Fig. 1B) .
According to the expression of cytokeratins and EMT markers in CTC we had four subgroups of patients: (1) (Fig. 1C) . Figure 2 .
The presence of mesenchymal markers in CTC lacking CK expression is shown in
In all 16 blood samples from healthy donors we failed to find expression of vimentin and fibronectin (Fig. 3) . biopsy' offered an alternative strategy to monitor cancer evolution and response to therapies [8] . Despite [3] .
Discussion

In the era of the 'microscopic revolution' cancer has been rethought at a single-cell level. Data are indeed increasing which support the prognostic value of CTC, in terms of PFS and OS, in metastatic breast cancer patients. The intriguing idea of a 'liquid
In a very recent work, questions have been raised as to whether negative CTCs and 'undetectable' CTCs should be differently interpreted [6] .
Indeed 
